Quantcast

Latest Pralatrexate Stories

2015-03-26 12:30:11

RnRMarketResearch.com adds "T-Cell Leukemia and Peripheral T-Cell Lymphomas - Pipeline Review, H1 2015" to its store.

2010-11-29 14:36:45

The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 – 6.

2009-12-17 00:45:00

SEATTLE, Dec. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on February 10, 2010 the U.S.

2009-11-23 13:03:00

Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). FORT WASHINGTON, Pa., Nov.

2009-11-10 08:12:00

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors.

2009-10-15 08:02:00

NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma.

2009-09-28 13:34:00

MENLO PARK, Calif. and NEW YORK and BIRMINGHAM, Ala., Sept. 28 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

2009-09-28 07:36:08

The U.S.


Word of the Day
bowerly
  • Large; stout; burly.
The word 'bowerly' is an alteration of 'burly'.